EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

24 May 2019
Imatinib medac - Public statement
EMA/290150/2019
EMEA/H/C/002692

Public statement

Imatinib medac

Withdrawal of the marketing authorisation in the European Union

On 14 February 2019, the European Commission withdrew the marketing authorisation for Imatinib medac (imatinib) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, medac Gesellschaft fur klinische Spezialpraparate mbH, which notified the European Commission of its decisionto permanently discontinue the marketing of the product for commercial reasons.

Imatinib medac was granted marketing authorisation in the EU on 25 September 2013 for treatment of leukaemia. The marketing authorisation was initially valid for a 5-year period.

Imatinib medac was a generic medicine of Glivec for treatment of leukaemia. There are other generic medicinal products of Glivec authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Imatinib medac will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

© European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged.